BHV-2100

N/A

Report date: 2026/03/09 13:22:54
NMEFirst In Class

Base Information

Drug NameBHV-2100
Drug Alias NameBHV-2100
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransient receptor potential cation channel subfamily M member 3 antagonists
TargetsTransient receptor potential cation channel subfamily M member 3
Therapy Area/IndicationsPainNeuralgiaMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKu LeuvenCentre for Drug Design and Discovery
China Registration ClassN/A

Develop Information

Active CompaniesBiohaven LtdBiohaven Therapeutics LtdBiohaven Pharmaceuticals Inc +[4] 
Inactive CompaniesN/A
Active IndicationsPainNeuralgiaMigraine Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A